Coeptis Therapeutics Has Expanded Its Exclusive License Agreement With The University Of Pittsburgh To Include The SNAP-CAR Technology Platform In Natural Killer Cells
Author: Benzinga Newsdesk | October 11, 2023 07:37am
This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.
Posted In: COEP